Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

A at week 20 of post-treatment follow-up. Of the remaining 8 patients enrolled in Arm D, 4 discontinued due to adverse events prior to week 12, and 4 did not achieve RVR.

Interim 12-Week Safety Analysis of PROVE 1

In PROVE 1, the types of adverse events that have been commonly observed with interferon and ribavirin were seen across all treatment arms. The most common adverse events, regardless of treatment assignment, were fatigue, rash, headache and nausea. Gastrointestinal disorders, rash and anemia were more common in the telaprevir arms.

In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events through 12 weeks was 11% (19 of 175 patients), compared to 3% (2 of 75 patients) in the control arm. The difference between the two groups is due to the greater number of discontinuations due to rash, gastrointestinal disorders and anemia in the telaprevir arms compared to the control arm. The most common reason for treatment discontinuation in the telaprevir arms was rash (7 patients), and the median time to discontinuation in these patients was 64 days.

Webcast of Investor Presentation

Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Telaprevir (VX-950)

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents in development that specifically targets HCV. Vertex is conducting a global Phase 2b clinical development program for telaprevir consis
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:8/26/2014)... Research and Markets  has announced the addition of ... report to their offering. Intranasal drug delivery ... of drugs for the treatment of local diseases in ... non-allergic rhinitis and sinusitis. The nose is considered to ... systematic drug delivery. Continuous technological advancement ...
(Date:8/26/2014)... , Aug. 26, 2014   Quanta Aesthetic Lasers , ... North America , expands the offerings in their robust ... which is now available for shipping to medical spas, clinics, ... . The QuantaShape is manufactured in the Chianti ... General Project .  The device was previously sold as both ...
(Date:8/26/2014)...  When it comes to diabetes supplies, innovations are often ... happens to answer a real medical need. ... market, Timesulin shows how long it,s been since your ... or double insulin doses. Very easy to use, Timesulin ... insulin pen after an injection. There is no settings ...
Breaking Medicine Technology:Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3Another Italian Beauty Joins the Quanta Aesthetic Lasers Lineup 2Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2
... Popular antidepressants taken with tamoxifen can increase the risk ... May 30 A new study found that taking ... of breast cancer recurrence in women taking both medications. ... work effectively.(Logo: http://www.newscom.com/cgi-bin/prnh/20090530/DC24767LOGO ) ...
... Abstract # 25670ORLANDO, Fla., May 29 ... has selected new breast cancer research conducted ... in Detroit for posting on ASCO,s Web ... promising new therapeutic target for aggressive hormone ...
Cached Medicine Technology:New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 2Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 3
(Date:8/27/2014)... A recent University College London (UCL) ... the dental community disagrees on the best way to ... of dental advice suggested that some six different tooth-brushing ... more popular than the rest. , “The easiest ... floss your teeth regularly,” said Dr. Alexandre-Amir Aalam, DDS, ...
(Date:8/27/2014)... "It can be quite difficult to wipe one’s ... inventor from Lehigh Acres, Fla.," so I designed an ... task." He then created a prototype of his idea. ... to wipe and clean the behind thoroughly after going ... well as prevents direct contact with waste or anal ...
(Date:8/27/2014)... Neil Haley, the Total Tutor host of the ... out about the importance of capacity to grow a business. ... ViSalus and is now a 5 Star Ambassador, Vi Millionaire, ... book titled "The Playful and Powerful Warrior Within You!" and ... working out for over 1000 days straight. He is ...
(Date:8/27/2014)... City, Utah (PRWEB) August 27, 2014 ... advancing the business of healthcare, is pleased to ... a ground-breaking online recruitment resource specifically designed for ... is undergoing significant changes. To help address the ... workforce, and tighter budgets—AAPC launched CareerHealth.com . ...
(Date:8/27/2014)... IntelliSoft Group, LLC, a leading provider of credentialing, ... IntelliCred, IntelliApp and IntelliContract Version 14.2 at ... Annual Conference on September 16, 2014 at the SERESC ... improvements available in IntelliSoft’s Version 14.2 healthcare ... A new Contract Connection Tab connects the healthcare provider ...
Breaking Medicine News(10 mins):Health News:Americans Confused About How to Brush Teeth 2Health News:InventHelp Client's Device Helps a User Wipe Thoroughly After Going to the Bathroom (HLW-1300) 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 3Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 2Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 3Health News:IntelliSoft Group to Unveil Version 14.2 of IntelliCred, IntelliApp and IntelliContract at the New Hampshire Association of Medical Staff Services Annual Conference 2
... pressure as it has been urged to make emergency contraception ... Eschenbach, acting Commissioner of the FDA has been urged to ... to sell its morning after pill or Plan B without ... set of two pills that can prevent pregnancy if taken ...
... arrested for allegedly selling fake question papers of the Combined ... 17 districts in the state today, police said. ... held here for selling CPMT question papers, which later turned ... of K G Dental University, which organised the CPMT examinations ...
... drugs seem to hold many youth under a spell. Recent ... to the tune of an increase of 400%, ever since ... reiterated the need for specialized services to remedy this menace, ... the University of Glasgow, said: "These figures are shocking and ...
... is to be conducted among children in the age group ... the kids are following proper eating habits// and there by ... mainly to tackle the worsening health crisis. But the Children's ... the child’s parents about the test results would stigmatize some ...
... is the second most deadly cancer among women. Statistics reveals ... result of cervical cancer. Hence researchers were keen on finding ... way to the development of a vaccine with the potential ... cervical cancer. ,It is mainly caused by ...
... conducted at New York indicates that people suffering from symptomatic ... C// and manganese than their counterparts without the problem. ... Dr N. J. Wareham et al of Medical Research Council ... reduce the onset of asthma. ,This study revealed ...
Cached Medicine News:
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... Nellcor's most popular handheld oximeter has ... Oximetry platform and is now compatible with ... including the MAX-FAST Forehead Sensor and SoftCare ... Pulse Oximeter also incorporates Nellcor's latest advanced ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: